Crimson Publishers High Impact Journals

Showing posts with label gastroenterology journal impact factor. Show all posts
Showing posts with label gastroenterology journal impact factor. Show all posts

Tuesday, April 30, 2019

Can we Optimize Immune Checkpoint Inhibitors Efficacy in Digestive Oncology?: Crimson Publishers

Can we Optimize Immune Checkpoint Inhibitors Efficacy in Digestive Oncology? by Anthony Lopez* in Crimson Publishers: Crimson research
Immunotherapy is revolutionizing oncology, with a simple guiding principle: the host immune system has the potential to eradicate cancer, treatment consisting in optimizing immune actors' functions. Although significant results were demonstrated in patients with melanoma or lung cancer, objective response rate (ORR) is only 20% in digestive oncology. However, we can improve this situation by a better knowledge of anti-tumor immunity. For example, ORR is multiplied by two to three in case of PD-L1 (programmed death-ligand 1) overexpression or microsatellite instability (MSI). In a near future, we will certainly be able to take into account other biomarkers for building composite scores for assigning to each patient with digestive cancer an 'immune identity card' able to strongly predict immunotherapy efficacy.


For more open access journals in Crimson Publishers Please click on link: https://crimsonpublishers.com/
For more Articles on Crimson research Please click on: https://crimsonpublishers.com/gmr/


Thursday, September 27, 2018

Gastroenterology: Medicine & Research ((GMR) ISSN : 2637-7632, Impact Factor : 0.668)

 

Chronic renal dysfunction is a frequent and severe complication in solid-organ transplant recipients. Switching from calcineurin inhibitors (CNIs) to non-nephrotoxic mammalian target of rapamycine inhibitors (mTORi) such as everolimus (EVR) can improve renal function in these patients. Single center prospective study by Castroagudin et al. [1] has shown an improvement of renal function after addition of the EVR to primary immunosuppression and reducing the CNIs [1]. The conclusion of the recently conducted global clinical randomized trial H23O4 involving the EVR was that the introduction of EVR with tacrolimus (TAC) reduction from day 30 after liver transplantation achieved a superior renal function with no compromise in efficacy at 12 months after liver transplantation. 



Reevaluating ReveL Osteotomy: Gait, Function and Long-Term Outcomes in Hallux Valgus Correction: Crimson Publishers

  Reevaluating ReveL Osteotomy: Gait, Function and Long-Term Outcomes in Hallux Valgus Correction by Muhammad Khubaib Iftikhar in Orthoped...